Prostate Cancer Epidemiology and Risk Factors: What the Global and Iranian Data Tell Us
Introduction
Prostate cancer occupies a paradoxical position in global oncology. It is simultaneously one of the most common cancers in men worldwide — the second most frequently diagnosed male malignancy globally — and one of the most geographically variable, with incidence rates differing by more than 60-fold between the highest-burden nations and the lowest. This extraordinary variation is not random. It encodes critical information about the biological, environmental, dietary, and genetic factors that drive prostate cancer risk — and understanding that variation is essential to prevention, early detection, and resource allocation.
Iran and the broader Middle Eastern region present a particularly instructive case study: the incidence of prostate cancer in Iran is very low as compared to Western countries, yet rates are rising. Examining why this is, and what risk factors are operating, illuminates the global epidemiology of this disease in ways that benefit patients and clinicians everywhere.
The Global Burden of Prostate Cancer
Scale and Mortality
Prostate cancer is a disease of staggering global prevalence:
- Prostate cancer is presently one of the major health concerns in the world. It is globally the second most frequent malignancy and the fifth leading cause of cancer deaths for males.
- Approximately 1.4 million new cases were recorded globally in 2016
- Over 375,000 deaths annually are attributed to prostate cancer worldwide
- The lifetime risk of diagnosis in Western men is approximately 1 in 8
Yet despite these numbers, the majority of prostate cancers follow an indolent course — many men die with prostate cancer rather than from it, and the challenge of modern oncology is distinguishing clinically significant disease from that which requires only monitoring.
The Geographic Disparity
The most striking feature of prostate cancer epidemiology is its extraordinary geographic variation:
| Region | Age-Standardized Incidence Rate (per 100,000) |
| Australia/New Zealand | ~111.6 |
| North America (US, Canada) | ~97.2 |
| Western Europe | ~62–85 |
| Caribbean | ~79 |
| Sub-Saharan Africa | ~26–38 |
| Turkey | ~40.6 |
| Lebanon | ~37.2 |
| Iran | ~5.1–9.1 |
| South/Southeast Asia | ~4–8 |
| Bhutan/Nepal/Bangladesh | ~1.2–1.7 |
The highest incidence rate was observed in North America, and the lowest incidence rate was observed in South Asia.
This roughly 60-fold difference between the highest and lowest incidence regions is one of the largest geographic disparities of any cancer type — and it is not explained by genetics alone. The powerful influence of environment, diet, and lifestyle is demonstrated by migrant studies: men of Japanese or Chinese origin who migrate to the United States develop prostate cancer at rates approaching those of Western-born men within one to two generations, strongly implicating environmental and dietary factors as major contributors.
Prostate Cancer in Iran: An Evolving Epidemiological Picture
Historically Low but Rising Incidence
The age-standardized incidence rate of prostate carcinoma in five Iranian provinces was 5.1 per 100,000 person-years. No significant difference was seen in the age-standardized incidence rate of prostate cancer within the provinces studied.
Analysis of studies on the incidence of prostate cancer showed a crude rate of 7.1 per 100,000 population (95% CI: 5.6–8.6). The pooled age-standardized incidence rate was 8.7 per 100,000 (95% CI: 6.7–10.4). Studies performed in the period 2004–2012 had significantly higher pooled estimates of the crude incidence rate compared with those conducted in 1996–2003.
This rising trend is consistent across Iranian registry data and mirrors patterns seen across developing countries undergoing rapid epidemiological transition:
- Urbanization and westernization of diet
- Aging population structure
- Improving cancer registration and detection
- Increased PSA testing awareness
According to the report by the Ministry of Health in Iran, cancer is the third cause of death and prostate cancer is one of the ten most frequent cancers. A previous study revealed that it is the second most prevalent cancer among genitourinary cancers in Iranian males.
Explanations for Iran’s Low Baseline Rate
Multiple factors likely contribute to Iran’s comparatively low prostate cancer incidence:
- This can partly be explained by lack of a nationwide screening program, younger age structure, and quality of the cancer registration system in Iran.
- Dietary factors: traditional Iranian and Middle Eastern diets rich in tomatoes (lycopene), legumes, and green vegetables may be protective
- Genetic factors: different ancestral risk allele frequencies compared to European populations
- PSA screening patterns: lower rates of PSA-based opportunistic screening mean fewer incidental low-grade cancers are detected
- Age structure: Iran’s relatively younger population means fewer men are in the highest-risk age brackets
Established Risk Factors for Prostate Cancer
Age: The Dominant Risk Factor
Age is the single strongest non-modifiable risk factor for prostate cancer. The disease is exceedingly rare before age 40 and rises sharply thereafter:
- < 40 years: extremely rare (< 0.1% of cases)
- 40–59 years: increasing risk; approximately 1 in 40 men
- 60–69 years: highest incidence concentration
- 70+ years: autopsy studies find microscopic prostate cancer in 70–80% of men
The risk of prostate cancer was increased with aging (OR: 5.35, 95% CI: 2.17–13.19; P < 0.0001). In the Iranian context, the mean age at diagnosis is approximately 67 years — similar to Western populations.
Race and Ethnicity
Racial disparities in prostate cancer are among the most pronounced of any cancer:
- African-American men have the highest incidence rates in the world (~185 per 100,000) and approximately 2.5 times higher mortality than white American men
- Asian men have the lowest rates, with men of East and South Asian descent showing the most protective effect
- Middle Eastern men occupy an intermediate position — lower than European Americans but higher than South/East Asian populations
- These disparities reflect combinations of genetic ancestry, socioeconomic factors, healthcare access differences, and dietary and lifestyle patterns
Family History and Genetics
Prostate cancer has a well-documented hereditary component:
- Men with a first-degree relative (father or brother) with prostate cancer have approximately 2–3 times the population risk
- Men with two or more first-degree relatives have approximately 5–11 times the population risk
- BRCA2 mutations confer a 2–6 fold increased risk and are associated with more aggressive disease; BRCA1 mutations carry a more modest risk increase
- HOXB13 G84E mutation — particularly relevant in men of Northern European descent — confers substantially elevated risk in carriers
- Lynch syndrome (MLH1, MSH2 mutations) is associated with modestly increased prostate cancer risk
Genetic counseling and enhanced surveillance are recommended for men with strong family histories or known pathogenic mutations.
Hormonal Factors
Prostate cancer is androgen-dependent. Testosterone and its potent metabolite dihydrotestosterone (DHT) drive prostate cell proliferation and are permissive for prostate cancer development:
- Men castrated before puberty (e.g., historical eunuchs) essentially never develop prostate cancer
- 5-alpha reductase inhibitors (finasteride, dutasteride) — which reduce DHT levels — decrease prostate cancer detection in screening trials by approximately 25%, though concerns remain about grade shift to higher-risk cancers
- The role of circulating testosterone levels is complex — lower levels do not clearly protect against prostate cancer, and the relationship may be U-shaped
One unit elevation in serum estradiol and testosterone concentration was related to increase (OR: 1.04) and decrease (OR: 0.79) of prostate cancer risk, respectively. — a finding from Iranian case-control data suggesting that the estradiol-to-testosterone ratio may be particularly relevant.
Diet and Lifestyle Factors
Dietary patterns show the strongest evidence for modifiable risk in prostate cancer:
Potentially protective factors:
- Lycopene (in tomatoes, tomato products): most consistently studied; several meta-analyses support modest protective effect
- Green tea polyphenols (EGCG): strong preclinical evidence; epidemiological data from Asian populations supportive
- Selenium: mixed evidence; SELECT trial found no benefit from supplementation
- Vitamin D: observational data suggests protective association; trials inconclusive
- Plant-based diet: overall dietary patterns rich in vegetables and legumes associated with lower risk
Potentially harmful factors:
- High saturated fat intake: consistently associated with increased risk in epidemiological studies
- Obesity: associated with more aggressive and fatal prostate cancer, though not clearly with overall incidence
- Dairy/calcium intake: high calcium intake possibly associated with modest risk increase; mechanism involves IGF-1 pathway
Increasing dietary consumption of lycopene and fat was associated with declined (OR: 0.45) and increased (OR: 2.38) prostate cancer development, respectively.
Other Risk Factors Under Investigation
| Factor | Evidence Level | Direction of Association |
| Vasectomy | Inconsistent across studies | Possibly weak positive |
| Sexually transmitted infections (HPV, Trichomonas) | Suggestive but inconclusive | Possibly positive |
| Smoking | Weakly associated with aggressive disease | Modest positive |
| Physical activity | Protective for aggressive disease | Negative (protective) |
| Metabolic syndrome | Associated with higher-grade disease | Positive |
| Diabetes | Inversely associated | Negative (apparently protective) |
Cases were less likely to have a history of diabetes (OR: 0.34, 95% CI: 0.12–0.98; P = 0.04). — this inverse association between diabetes and prostate cancer risk has been confirmed in multiple large epidemiological studies and may reflect lower circulating insulin and IGF-1 levels in diabetic men.
Prevention Strategies: What the Evidence Supports
Primary Prevention
Based on current evidence, practical evidence-based prevention approaches include:
- Maintain a healthy weight — obesity links to more aggressive prostate cancer and worse outcomes
- Adopt a plant-rich diet — emphasize tomatoes, cruciferous vegetables, green tea, legumes, and fiber; reduce red and processed meat and high-fat dairy
- Regular physical activity — consistent evidence for protection against aggressive prostate cancer; aim for ≥ 150 minutes/week moderate aerobic activity
- Avoid smoking — associated with more aggressive disease and worse survival
- Discuss family history with your physician — genetic risk warrants earlier and more frequent surveillance
- Limit alcohol — heavy consumption associated with poorer prognosis in diagnosed men
Chemoprevention
The PCPT trial demonstrated that finasteride (5-alpha reductase inhibitor) reduced the detection of low-grade prostate cancer by 25% — but concerns about apparent increase in detection of high-grade (Gleason ≥ 7) cancers, though likely partly artifactual, have prevented widespread adoption. Current guidelines do not recommend routine chemoprevention but note it as an option for selected high-risk individuals in shared decision-making.
Screening: A Nuanced Recommendation
PSA-based prostate cancer screening is among the most debated topics in preventive oncology:
- The US PLCO and European ERSPC trials produced conflicting results on prostate cancer mortality benefit
- Current AUA guidelines recommend informed shared decision-making about PSA screening starting at age 55 for average-risk men; earlier discussion (age 40–45) for high-risk men (Black race, BRCA2 carriers, strong family history)
- Screening finds cancer, but overdiagnosis of indolent disease is a real concern — the 10-year National Academy of Medicine recommendations emphasize individualized risk-based rather than universal screening
Conclusion
Prostate cancer’s global epidemiology is a study in contrasts — ubiquitous in some populations, rare in others, rising across the developing world including Iran. Understanding these patterns is not merely academic: they point to modifiable dietary and lifestyle factors that represent real opportunities for prevention, and they highlight the importance of ethnicity-appropriate screening thresholds and genetic risk awareness.
The incidence of prostate cancer in Iran is very low compared to Western countries — yet its rising trend, driven by aging demographics and lifestyle westernization, demands proactive epidemiological surveillance and prevention investment. The risk factor profile — age, family history, race, diet, hormonal milieu — is increasingly well characterized, and the evidence base for prevention is strengthening.
Your next steps:
- Know your family history — share it with your primary care physician to determine whether earlier or more frequent PSA monitoring is appropriate
- If you are of Black/African ancestry or carry BRCA2/BRCA1 mutations, request a prostate cancer risk discussion starting at age 40
- Adopt a Mediterranean or plant-rich dietary pattern — the most evidence-supported modifiable preventive strategy
- Engage in regular aerobic physical activity — 150+ minutes per week is consistently associated with lower aggressive prostate cancer risk
- If you are considering PSA screening, have an informed discussion with your doctor about benefits, harms, and your personal risk profile before testing
- Support population-level prostate cancer registries in your country — better epidemiological data drives better prevention policy